Sandoz has agreed to wait until March 2030 to launch a generic version of Adamas Pharmaceuticals’ Gocovri (adamantadine) extended-release capsules in the US. However, Novartis’ generics division may be able to bring that entry date forward if volume sales of the dyskinesia treatment decline versus current levels.
Under the terms of a settlement of patent litigation that saw the two firms submit a